Overview

* Lexicon Q3 2025 total revenue increased to $14.2 mln, driven by licensing revenue

* Net loss for Q3 2025 was $12.8 mln, significantly lower than Q3 2024

* R&D expenses decreased to $18.8 mln due to lower external research costs

Outlook

* Lexicon expects 2026 to be pivotal for strategic initiatives

* FDA feedback on Zynquista resubmission expected in Q4 2025

* Novo Nordisk preparing IND submission for LX9851, triggering potential milestone payments

Result Drivers

* LICENSING REVENUE - Increase in Q3 2025 revenue attributed to licensing agreement with Novo Nordisk

* EXPENSE REDUCTION - Decrease in R&D and SG&A expenses due to strategic repositioning and reduced marketing efforts

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 $1.01

Product mln

Revenue

Q3 EPS -$0.04

Q3 Net -$12.77

Income mln

Q3 Basic -$0.04

EPS

Q3 $26.37

Operatin mln

g

Expenses

Q3 -$12.19

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Lexicon Pharmaceuticals Inc ( LXRX ) is $1.90, about 27.4% above its November 5 closing price of $1.38

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)